Amgen has agreed to buy Horizon Therapeutics in a deal valued at $27.8 billion. The Thousand Oak, California-based biopharmaceutical company announced on Monday that it will pay $116.50 in cash for each share of Horizon. Based in Dublin, Horizon develops potential treatments for rare, autoimmune, and inflammatory diseases. Horizon manufactures Tepezza, a thyroid eye disease [...] The post How Amgen Buying Horizon Therapeutics Could Impact TTAC appeared first on ETF Trends .